Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday.

Recursion extended its winning streak to a fourth day on Wednesday, jumping 6.81 percent to close at $4.86 apiece as investors gobbled up more shares ahead of expected business updates from its participation in two conferences next week.

In a statement on Tuesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) said that its president and CEO, Najat Khan, would present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, as well as the 28th Annual Needham Growth Conference on Friday, January 16.

Investors will be closely watching out for updated guidance about its earnings performance in 2025, pipeline updates, as well as its outlook for 2026.

Last month, investment firm JPMorgan turned bullish about Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) after upgrading the stock to “overweight” from “neutral” previously, while also raising its price target to $11 from $10.

The change followed solid results from the latest clinical trial of therapy candidate, REC-4881, which aims to treat Familial Adenomatous Polyposis.

According to JPMorgan, REC-4881 holds the potential to generate $1 billion in sales in the United States.

While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.